Latest Information Update: 30 Oct 2003
At a glance
- Originator Shire Pharmaceuticals
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Epilepsy
Most Recent Events
- 28 Feb 2003 Discontinued - Preclinical for Epilepsy (unspecified route)
- 30 Nov 2001 Preclinical development for Epilepsy (Unknown route)